I think it's far to early to attempt comparison of IMGN's drugs with others from the ASH abstracts. The trial to date is escalating dose and continues to escalate with positive results seen. At the quarterly report it was stated that additional escalations would be reported on at ASH, and they continue to escalate. What we do know is the drug in trials is IMGN's version of a drug SGEN had tried, and abandoned with unacceptable side effects at much lower dose levels than IMGN has already achieved, without the side effects. In short, in at least this form of cancer IMGN's technology is superior.
Remember, the drugs at ASH are two of IMGN's newest IGN drugs, which are partnered with ASH. IMGN's most advanced drug IMGN853 is in a Phase 3 Trial as a monotherapy, which won't report for a couple years unless futility is determined. It is however being tested in a few Phase 1/2's in combination with other drugs and results there have been strong to date, and more data should be reported by end of the year. This drug has not been partnered, but IMGN has been clear that they want a ROW partnership, with IMGN maintaining sole ownership in the U.S. I believe this is where the big boost in share price should come from nearer term, the new IGN drugs are at least a few years further to approval while 853 should be approved in 2020 or sooner.
Gary |
